⚠ LIVE — European Consumer Safety Watch 💊 Medicines: 34 in last 7 days 🍎 Food: 1 in last 7 days 🧸 Products: 0 in last 7 days 🟢 Monitoring: EMA · RASFF · NVWA · FAGG · FAVV · EFSA · Safety Gate ⏱ Last fetch: 3 hours ago ⚠ LIVE — European Consumer Safety Watch 💊 Medicines: 34 in last 7 days 🍎 Food: 1 in last 7 days 🧸 Products: 0 in last 7 days 🟢 Monitoring: EMA · RASFF · NVWA · FAGG · FAVV · EFSA · Safety Gate ⏱ Last fetch: 3 hours ago
🛡️ EUSW
🇬🇧
💊

Elahere

mirvetuximab soravtansine
Ovarian Neoplasms;Fallopian Tube Neoplasms;Peritoneal Neoplasms
✅ Authorised
No active alerts
This medicine has no ongoing shortages, safety letters or recalls.

What it's used for

Elahere as monotherapy is indicated for the treatment of adult patients with folate receptor-alpha (FRα) positive, platinum-resistant high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens.

⚠️ Patient safety

No

⚠️ We aggregate official notices. We do not give medical advice. For medical or legal decisions, consult the source agency and a qualified professional.